MINNEAPOLIS & DUBLIN, Calif.--(BUSINESS WIRE)--Oct. 26, 2005--MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today provided a regulatory updates for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS). The MDS New Drug Application (NDA) is currently under review by the U.S. Food and Drug Administration (FDA), and the Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMEA).
